Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

AKMANSU, MÜGE; Buyukberber, SÜLEYMAN; Iren, Sevilay; Demirci, Umut; Kanyilmaz, Gul; Coskun, Ugur; BORA, HÜSEYİN

doi:10.1159/000323204

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

AKMANSU M., Buyukberber S., Iren S., Demirci U., Kanyilmaz G., Coskun U., ...Daha Fazla

CASE REPORTS IN ONCOLOGY, cilt.3, sa.3, ss.480-488, 2010 (ESCI, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 3 Sayı: 3
Basım Tarihi: 2010
Doi Numarası: 10.1159/000323204
Dergi Adı: CASE REPORTS IN ONCOLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.480-488
Anahtar Kelimeler: Cetuximab, Head and neck carcinoma, Irradiation, Radiotherapy, Recurrence
Gazi Üniversitesi Adresli: Evet

Özet

We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and annual mean survival rate is 59.3%.